866-997-4948(US-Canada Toll Free)

Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies

Published By :

GBI Research

Published Date : Jan 2011

Category :

Prescription Drugs

No. of Pages : 107 Pages


GBI Research, the leading business intelligence provider, has released its latest research, Anticonvulsants Market to 2016 Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies, which provides insights into global anticonvulsant market and market forecast until 2016.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

The report provides an in-depth analysis of the top five therapeutic indications for which often anticonvulsants are prescribed which includes epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder. The report also examines the Global anticonvulsant treatment usage patterns for the covered indication. In addition, the report also includes insights into the anticonvulsant R&D pipeline. 

GBI Research analysis shows that the overall global anticonvulsant market for the five indications epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder is valued at $7.75 billion in 2009. The market is expected to witness a decline at a CAGR of 0.1% for the forecast period and will reach $7.7 billion by 2016. 

Patent expiries of leading anticonvulsant followed by generic erosions are the main reason for decline in anticonvulsant market. However expected launch of new anticonvulsants is expected to stabilize the market in future.

The US was the largest region for the anticonvulsant market in terms of revenue, accounting for 52% followed by Top five countries of Europe and Japan which contributed 36% and 12% respectively.

The top pharmaceutical companies in anticonvulsant market companies Pfizer, Novartis, Abbott, UCB, Johnson & Johnson and GlaxoSmithKline. Large amount of fragmentation in the market provides significant scope for consolidation through mergers and acquisitions.

Scope

The scope of this report includes - 

  • Data and analysis on the global anticonvulsant market.
  • Annualized market data for the anticonvulsant market from 2002 to 2009, with forecasts to 2016.
  • Market data on the therapeutic landscape which covers epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
  • Key drivers and restraints that have had a significant impact on the market and on each indication.
  • The competitive landscape of the global anticonvulsant market which includes companies such as Pfizer, Novartis, Abbott, UCB, Johnson & Johnson and GlaxoSmithKline.
  • Key M&A activities and Licensing Agreements that took place from 2005 to 2010 in the global anticonvulsant market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to - 

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
  • Device a more tailored country strategy through the understanding of key drivers and barriers of the regions anticonvulsant market.
  • Develop key strategic initiatives by understanding the key focus areas and top selling anticonvulsant molecules of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents

1 Table of Contents 3

1.1 List of Tables 6
1.2 List of Figures 8

2 Anticonvulsant Market to 2016 Introduction 10
2.1 GBI Research Report Guidance 13

3 Anticonvulsant Market to 2016 Market Overview 14
3.1 Introduction 14
3.2 Revenue Forecasts for the Global Anticonvulsant Market 14
3.2.1 Revenue 14
3.2.2 Annual Cost of Treatment (ACT) 15

4 Anticonvulsant Market to 2016 Geographical Landscape 16
4.1 Revenue Analysis by Geography 16
4.2 The US 17
4.2.1 Revenue 17
4.2.2 Annual Cost of Treatment 18
4.3 Top Five Countries of Europe 19
4.3.1 Revenue 19
4.3.2 Annual Cost of Treatment 20
4.4 Japan 21
4.4.1 Revenue 21
4.4.2 Annual Cost of Treatment 22

5 Anticonvulsant Market to 2016 Therapeutic Landscape 23
5.1 Anticonvulsant Market for Bipolar Disorder 23
5.1.1 Introduction 23
5.1.2 Revenue 24
5.1.3 Annual Cost of Treatment 26
5.1.4 Treatment Usage Patterns 27
5.2 Drivers and Barriers to the Anticonvulsant Market for Bipolar Disorder 32
5.2.1 Drivers for the Bipolar Disorder Market 32
5.2.2 Barriers for the Disorder Market 32
5.3 Anticonvulsant Market for Neuropathic Pain 33
5.3.1 Introduction 33
5.3.2 Revenue 34
5.3.3 Annual Cost of Treatment 36
5.3.4 Treatment Usage Patterns 37
5.4 Drivers and Barriers to Anticonvulsant Market of Neuropathic Pain 42
5.4.1 Drivers for Neuropathic Pain Market 42
5.4.2 Restraints for Neuropathic Pain Market 42
5.5 Anticonvulsant Market for Fibromyalgia 43
5.5.1 Introduction 43
5.5.2 Revenue 44
5.5.3 Annual Cost of Treatment 46
5.5.4 Treatment Usage Patterns 47
5.6 Drivers and Barriers to Anticonvulsant Market of Fibromyalgia 53
5.6.1 Drivers for the Fibromyalgia Therapeutics Market 53
5.6.2 Barriers for the Fibromyalgia Therapeutics Market 53
5.7 Anticonvulsant Market for Migraine 54
5.7.1 Introduction 54
5.7.2 Revenue 55
5.7.3 Annual Cost of Treatment 57
5.7.4 Treatment Usage Patterns 58
5.8 Drivers and Barriers to Anticonvulsant Market for Migraine 63
5.8.1 Drivers for the Migraine Market 63
5.8.2 Barriers for the Migraine Market 63
5.9 Anticonvulsant Market for Epilepsy 64
5.9.1 Introduction 64
5.9.2 Revenue 64
5.9.3 Annual Cost of Treatment 67
5.9.4 Treatment Usage Patterns 68
5.10 Drivers and Barriers to Anticonvulsant Market for Epilepsy 73
5.10.1 Drivers to Anticonvulsant Market for Epilepsy 73
5.10.2 Barriers to Anticonvulsant Market for Epilepsy 74

6 Anticonvulsant Market to 2016 Product Pipeline Analysis 75
6.1 Introduction 75
6.1.1 Research and Development Pipeline 75
6.2 Profiles of Promising Anticonvulsant Drugs 78
6.2.1 Brivaracetam 78
6.2.2 Clonazepam + Levetiracetam 78
6.2.3 Epliga 78
6.2.4 Potiga 79
6.2.5 USL 255 79
6.2.6 Vanquix 79
6.2.7 Trokesa 80
6.2.8 E2007 80
6.2.9 Vimpat (Lacosamide) 80

7 Anticonvulsant Market to 2016 Competitive Landscape 81
7.1 Market Share Analysis 81
7.2 Pfizer Inc. 82
7.2.1 Company Overview 82
7.2.2 Business Overview 82
7.2.3 SWOT Analysis 83
7.3 UCB Group 83
7.3.1 Company Overview 83
7.3.2 Business Overview 83
7.3.3 SWOT Analysis 84
7.4 Johnson & Johnson (J&J) 85
7.4.1 Company Overview 85
7.4.2 Business Overview 85
7.4.3 SWOT Analysis 86
7.5 GlaxoSmithKline plc 87
7.5.1 Company Overview 87
7.5.2 Business Overview 87
7.5.3 SWOT Analysis 88
7.6 Abbott Laboratories 88
7.6.1 Company Overview 88
7.6.2 Business Overview 89
7.6.3 SWOT Analysis 89
7.7 Novartis AG 90
7.7.1 Company Overview 90
7.7.2 Business Overview 90
7.7.3 SWOT Analysis 91

8 Anticonvulsant Market to 2016 M&A Landscape 92
8.1 M&A Deals 2005-2010 92
8.1.1 Deal Summary 93
8.1.2 Deals by Value 96
8.1.3 Deals by Geography 97
8.2 Licensing Deals 2005-2010 98
8.2.1 Summary of Licensing Deals (2009-2010) 99
8.3 Co-developments Deals 2005-2010 100
8.3.1 Summary of Co-development Deals (2009-2010) 101

9 Anticonvulsants Market to 2016 Appendix 102
9.1 Market Definitions 102
9.2 Abbreviations 102
9.3 Research Methodology 103
9.3.1 Coverage 103
9.3.2 Secondary Research 103
9.3.3 Primary Research 104
9.3.4 Expert Panel Validation 106
9.4 Contact Us 106
9.5 Disclaimer 106
9.6 Sources 106

List of Table


Table 1: Anticonvulsant Market, Global Revenue of Top Selling Anticonvulsants ($m), Approved Indications, 2007-2009 11
Table 2: Anticonvulsant Market, Future Promising Players in Anticonvulsant Market 12
Table 3: Anticonvulsant Market, Global, Revenue Forecasts ($m), 2001-2009 14
Table 4: Anticonvulsant Market, Global, Revenue Forecasts ($m), 2009-2016 15
Table 5: Anticonvulsant Market, Global, Annual Cost of Treatment ($), 2001-2009 15
Table 6: Anticonvulsant Market, Global, Annual Cost of Treatment ($), 2009-2016 15
Table 7: Anticonvulsant Market, Global, Revenue Analysis by Geography ($m), 2001-2009 16
Table 8: Anticonvulsant Market, Global, Revenue Analysis by Geography ($m), 2009-2016 16
Table 9: Anticonvulsant Market, The US, Revenue ($m) , 2001-2009 17
Table 10: Anticonvulsant Market, The US, Revenue Forecasts ($m), 2009-2016 17
Table 11: Anticonvulsant Market, The US, Annual Cost of Treatment($), 2001-2009 18
Table 12: Anticonvulsant Market, The US, Annual Cost of Treatment ($), 2009-2016 18
Table 13: Anticonvulsant Market, Top Five Countries of Europe, Revenue ($m), 2001-2009 19
Table 14: Anticonvulsant Market, Top Five Countries of Europe, Revenue Forecasts ($m),
2009-2016 19
Table 15: Anticonvulsant Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2001-2009 20
Table 16: Anticonvulsant Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2009-2016 20
Table 17: Anticonvulsant Market, Japan, Revenue ($m), 2001-2009 21
Table 18: Anticonvulsant Market, Japan, Revenue Forecast ($m), 2009-2016 21
Table 19: Anticonvulsant Market, Japan, Annual Cost of Treatment ($), 2001-2009 22
Table 20: Anticonvulsant Market, Japan, Annual Cost of Treatment ($), 2009-2016 22
Table 21: Anticonvulsant Market, Bipolar Disorder, Global, Revenue ($m), 2001-2009 24
Table 22: Anticonvulsant Market, Bipolar Disorder, Global Revenue Forecast ($m), 2009-2016 24
Table 23: Anticonvulsant Market, Bipolar Disorder, Revenue by Geography ($m), 2001-2009 25
Table 24: Anticonvulsant Market, Bipolar Disorder, Revenue by Geography ($m),2009-2016 25
Table 25: Anticonvulsant Market, Bipolar Disorder, Annual Cost of Treatment by Geography ($), 2001-2009 26
Table 26: Anticonvulsant Market, Bipolar Disorder, Annual Cost of Treatment by Geography ($), 2009-2016 26
Table 27: Anticonvulsant Market, Bipolar Disorder, Global Treatment Usage Patterns (Million), 2001-2009 27
Table 28: Anticonvulsant Market, Bipolar Disorder, Global Treatment Usage Patterns (Million), 2009-2016 28
Table 29: Anticonvulsant Market, Neuropathic Pain, Global Revenue ($m), 2001-2009 34
Table 30: Anticonvulsant Market, Neuropathic Pain, Global Revenue Forecast ($m), 2009-2016 34
Table 31: Anticonvulsant Market, Neuropathic Pain, Revenue by Geography, ($m),2001-2009 35
Table 32: Anticonvulsant Market, Neuropathic Pain, Revenue by Geography ($m), 2009-2016 35
Table 33: Anticonvulsant Market for Neuropathic Pain, Global, Annual Cost of Treatment ($), 2001-2009 36
Table 34: Anticonvulsant Market for Neuropathic Pain, Global, Annual Cost of Treatment($), 2009-2016 36
Table 35: Anticonvulsant Market, Neuropathic Pain, Global Treatment Usage Patterns (Million), 2001-2009 37
Table 36: Anticonvulsant Market, Neuropathic Pain, Global Treatment Usage Patterns (Million), 2009-2016 38
Table 37: Anticonvulsant Market, Fibromyalgia, Global Revenue Forecasts ($m), 2001-2009 44
Table 38: Anticonvulsant Market, Fibromyalgia, Global Revenue Forecasts ($m), 2009-2016 44
Table 39: Anticonvulsant Market, Fibromyalgia, Revenue by Geography ($m),2001-2009 45
Table 40: Anticonvulsant Market, Fibromyalgia, Revenue by Geography ($m),2009-2016 45
Table 41: Anticonvulsant Market, Fibromyalgia, Annual Cost of Treatment by Geography ($), 2001-2009 46
Table 42: Anticonvulsant Market, Fibromyalgia, Annual Cost of Treatment by Geography ($), 2009-2016 47
Table 43: Anticonvulsant Market, Fibromyalgia, Treatment Usage Patterns (Million), 2001-2009 48
Table 44: Anticonvulsant Market, Fibromyalgia, Treatment Usage Patterns (Million), 2009-2016 48
Table 45: Anticonvulsant Market, Migraine, Global Revenue Forecasts ($m), 2001-2009 55
Table 46: Anticonvulsant Market, Migraine, Global Revenue Forecasts ($m), 2009-2016 55
Table 47: Anticonvulsant Market, Migraine, Revenue by Geography ($m), 2001-2009 56
Table 48: Anticonvulsant Market, Migraine, Revenue by Geography ($m),2009-2016 56
Table 49: Anticonvulsant Market, Migraine, Global, Annual Cost of Treatment ($), 2001-2009 57
Table 50: Anticonvulsant Market, Migraine, Global, Annual Cost of Treatment ($), 2009-2016 57
Table 51: Anticonvulsant Market, Migraine, Global Treatment Usage Patterns (Million), 2001-2009 58
Table 52: Anticonvulsant Market, Migraine, Global Treatment Usage Patterns (Million), 2009-2016 58
Table 53: Anticonvulsant Market, Epilepsy, Global Revenue Forecasts ($m), 2001-2009 65
Table 54: Anticonvulsant Market, Epilepsy, Global Revenue Forecasts ($m), 2009-2016 65
Table 55: Anticonvulsant Market, Epilepsy, Revenue by Geography, ($m),2001-2009 66
Table 56: Anticonvulsant Market, Epilepsy, Revenue by Geography, ($m),2009-2016 66
Table 57: Anticonvulsant Market for Epilepsy, Global, Annual Cost of Treatment ($), 2001-2009 67
Table 58: Anticonvulsant Market for Epilepsy, Global, Annual Cost of Treatment ($), 2009-2016 67
Table 59: Anticonvulsant Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2001-2009 68
Table 60: Anticonvulsant Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2009-2016 68
Table 61: Anticonvulsant Market, Molecules in Phase III Clinical Trial,2010 73
Table 62: Anticonvulsant Market, Discovery Stage Molecule,2010 75
Table 63: Anticonvulsant Market, Phase I Stage Molecule,2010 76
Table 64: Anticonvulsant Market, Phase II Stage Molecules,2010 76
Table 65: Anticonvulsant Market,, Phase III Stage Molecules,2010 77
Table 66: Anticonvulsant Market, Filed Molecules,2010 77
Table 67: Anticonvulsant Market, Global Major M&A Deals, 2005-2010 92
Table 68: Anticonvulsant Market, Global Licensing Deal, 2005-2010 98
Table 69: Anticonvulsant Market, Global Major Co-developments Deals , 2005-2010 100

List of Chart


Figure 1: Anticonvulsant Market, Global Revenue of Top Selling Anticonvulsant,($m), 2008-2009 11
Figure 2: Anticonvulsant Market, Global, Revenue Forecasts ($m), 2001-2016 14
Figure 3: Anticonvulsant Market, Global, Annual Cost of Treatment ($), 2001-2016 15
Figure 4: Anticonvulsant Market, Global, Revenue Analysis by Geography ($m), 2001-2016 16
Figure 5: Anticonvulsant Market, The US, Revenue Forecasts ($m), 2001-2016 17
Figure 6: Anticonvulsant Market, The US, Annual Cost of Treatment ($), 2001-2016 18
Figure 7: Anticonvulsant Market, Top Five Countries of Europe, Revenue Forecasts ($m),
2001-2016 19
Figure 8: Anticonvulsant Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2001-2016 20
Figure 9: Anticonvulsant Market, Japan, Revenue Forecast ($m), 2001-2016 21
Figure 10: Anticonvulsant Market, Japan, Annual Cost of Treatment ($), 2001-2016 22
Figure 11: Anticonvulsant Market, Bipolar Disorder, Global Revenue Forecasts ($m), 2001-2016 24
Figure 12: Anticonvulsant Market, Bipolar Disorder, Revenue by Geography ($m), 2001-2016 25
Figure 13: Anticonvulsant Market, Bipolar Disorder, Annual Cost of Treatment by Geography ($), 2001-2016 26
Figure 14: Anticonvulsant Market, Bipolar Disorder, Global Treatment Usage Patterns (Million), 2001-2016 27
Figure 15: Anticonvulsant Market, Bipolar Disorder, Global Diseased Population (Million),
2001-2016 28
Figure 16: Anticonvulsant Market, Bipolar Disorder, Global Treatment Seeking Population (Million), 2001-2016 29
Figure 17: Anticonvulsant Market, Bipolar Disorder, Global Diagnosis Population (Million),
2001-2016 30
Figure 18: Anticonvulsant Market, Bipolar Disorder, Global Prescription Population (Million),
2001-2016 31
Figure 19:Anticonvulsant Market, Bipolar Disorder, Global Market Drivers and Barriers, 2009-2016 32
Figure 20: Anticonvulsant Market, Neuropathic Pain, Global Revenue Forecasts ($m), 2001-2016 34
Figure 21: Anticonvulsant Market, Neuropathic Pain, Revenue by Geography ($m), 2001-2016 35
Figure 22: Anticonvulsant Market,Neuropathic Pain, Annual Cost of Treatment ($) by Geography, 2001-2016 36
Figure 23: Anticonvulsant Market,Neuropathic Pain, Global Treatment Usage Patterns (Million), 2001-2016 37
Figure 24: Anticonvulsant Market, Neuropathic Pain, Global Diseased Population (Million),
2001-2016 38
Figure 25: Anticonvulsant Market, Neuropathic Pain, Global Treatment Seeking Population (Million), 2001-2016 39
Figure 26: Anticonvulsant Market,Neuropathic Pain, Global Diagnosis Population (Million),
2001-2016 40
Figure 27: Anticonvulsant Market, Neuropathic Pain, Global Prescription Population (Million),
2001-2016 41
Figure 28: Anticonvulsant Market, Neuropathic Pain, Global Drivers and Barriers, 2009-2016 42
Figure 29: Anticonvulsant Market, Fibromyalgia, Global Revenue Forecasts ($m), 2001-2016 44
Figure 30: Anticonvulsant Market, Fibromyalgia, Revenue by Geography ($m),2001-2016 45
Figure 31: Anticonvulsant Market, Fibromyalgia, Annual Cost of Treatment by Geography ($), 2001-2016 46
Figure 32: Anticonvulsant Market, Fibromyalgia, Treatment Usage Patterns (Million), 2001-2016 47
Figure 33: Anticonvulsant Market, Fibromyalgia, Global Diseased Population (Million), 2001-2016 49
Figure 34: Anticonvulsant Market, Fibromyalgia, Global Treatment Seeking Population (Million), 2001-2016 50
Figure 35: Anticonvulsant Market, Fibromyalgia, Global Diagnosis Population (Million), 2001-2016 51
Figure 36: Anticonvulsant Market, Fibromyalgia, Global Prescription Population (Million),
2001-2016 52
Figure 37: Anticonvulsant Market, Fibromyalgia, Global Market Drivers and Barriers, 2009-2016 53
Figure 38: Anticonvulsant Market, Migraine, Global Revenue Forecasts ($m), 2001-2016 55
Figure 39: Anticonvulsant Market, Migraine, Revenue by Geography, ($m),2001-2016 56
Figure 40: Anticonvulsant Market, Migraine, Global, Annual Cost of Treatment ($), 2001-2016 57
Figure 41: Anticonvulsant Market, Migraine, Global Treatment Usage Patterns (Million), 2001-2016 58
Figure 42: Anticonvulsant Market, Migraine, Global Diseased Population (Million), 2001-2016 59
Figure 43: Anticonvulsant Market, Migraine, Global Treatment Seeking Population (Million),
2001-2016 60
Figure 44: Anticonvulsant Market, Migraine, Global Diagnosis Population (Million), 2001-2016 61
Figure 45: Anticonvulsant Market, Migraine, Global Prescription Population (Million), 2001-2016 62
Figure 46: Anticonvulsant Market, Migraine, Global Market Drivers and Barriers,2009-2016 63
Figure 47: Anticonvulsant Market, Epilepsy, Global Revenue Forecasts ($m), 2001-2016 64
Figure 48: Anticonvulsant Market, Epilepsy, Revenue by Geography ($m), 2001-2016 66
Figure 49: Anticonvulsant Market for Epilepsy, Global, Annual Cost of Treatment ($), 2001-2016 67
Figure 50: Anticonvulsant Market, Epilepsy, Global Treatment Usage Patterns (Million), 2001-2016 68
Figure 51: Anticonvulsant Market, Epilepsy, Global Diseased Population (Million), 2001-2016 69
Figure 52: Anticonvulsant Market, Epilepsy, Global, Treatment Seeking Population (Million), 2001-2016 70
Figure 53: Anticonvulsant Market, Epilepsy, Global, Diagnosis Population (Million), 2001-2016 71
Figure 54: Anticonvulsant Market, Epilepsy, Global, Prescription Population (Million), 2001-2016 72
Figure 55: Anticonvulsant Market, Epilepsy, Global Market Drivers and Barriers, 2009-2016 74
Figure 56: Anticonvulsant Market, Global Product Pipeline by Phase (%), 2010 75
Figure 57: Anticonvulsant Market, Global Top Companies Share (%), 2009 81
Figure 58: Anticonvulsant Market, Global Top Companies Share (%), 2008 81
Figure 59: SWOT Analysis of Pfizer 83
Figure 60: SWOT Analysis of UCB 84
Figure 61: SWOT Analysis of J&J 86
Figure 62: SWOT Analysis of GSK 88
Figure 63: SWOT Analysis of Abbott Laboratories 89
Figure 64: SWOT Analysis of Novartis 91
Figure 65: Anticonvulsant Market, Global Major M&A Deals by Deal Value,($m) 2005-2010 96
Figure 66: Anticonvulsant Market, Global Major M&A Deals by Geography, 2005-2010 97
Figure 67: Anticonvulsant Market, Global, Major Licensing Deals by Geography 2005-2010 99
Figure 68: GBI Research Market Forecasting Model 105

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *